T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma


Disclosures: S.Mu. has received honoraria and research funding from Novartis, BMS and Pfizer (not related to this study). S.L has received honoraria and research funding from Roche, Takeda, Bayer, Celgene and Janssen-Cilag (not related to this study). P.-L.K.-L. has received research funding from Roche, Sanofi and Pfizer (not related to this study). Other authors declare no conflicts of interest pertinent to the topic of this manuscript.

Contributions: S.-K.L. designed and conceived the study, analyzed data, and wrote the manuscript. M.P. M.A. and S.Ma. analyzed data. O.B. and T.P. performed mlHC analysis and analyzed the data. M.-L.K.-L. provided samples. P.-L.K.-L., O.K. and S.Mu. provided guidance and support. S.L designed and supervised the study and wrote the manuscript. All authors have read and approved the manuscript.